Gödecke GmbH

1. To evaluate the efficacy of pregabalin (300 - 450 mg/day) twice daily compared with placebo in relieving fibromyalgia-related pain symptoms; 2. If the first study objective is achieved, the second primary study objective is to evaluate the efficacy of pregabalin (twice daily) compared with placebo in the treatment of fibromyalgia (pain reduction, patient global assessment and functional improvement).

The purpose of this study by Pfizer is to allow subjects to take CP-690,550 for as long as they can tolerate and safely, until at least two years after the first global approval of CP-690,550 for the treatment of rheumatoid arthritis or the study of CP-690,550 for the treatment of rheumatoid arthritis is terminated. The primary purpose is to understand the long-term safety and tolerability of 5mg BID and 10mg BID doses of CP-690,550 in the treatment of rheumatoid arthritis symptoms and signs; the secondary purpose is to evaluate the persistence of the efficacy of 5mg BID and 10mg BID doses of CP-690,550 in the treatment of rheumatoid arthritis symptoms and signs.